Cardiovascular Disease
$1.8T by 2050 (US)
Leading cause of death globally, costs projected to triple from current levels. [1]
Message Variants
Slide message designs from layouts/sections/
The Aging Crisis: The Problem We're Solving
The Problem
The Aging Crisis
Age-related diseases cost $1T+ annually in global healthcare
$ 1T+
annual global healthcare costs
Alzheimer's • Cancer • CVD • Diabetes • Renal Failure
Explore
Trillion-Dollar Diseases
A Handful of Conditions Drive Trillions in Cost
Diabetes
$966B per year (global)
Approaching $1T annually worldwide in direct health expenditure.
Cancer
#1 cost driver
Now the leading condition driving insurer medical costs globally, cited by 57% of insurers. [2]
Chronic Conditions
90% of US spend
Nearly all US healthcare spending goes to chronic and mental health conditions. [3]
The Gap
The System Extended Lifespan, But Not Healthspan
15 years
Years living with chronic disease, disability, or frailty [4]
US Demographics
A Silver Tsunami is Coming
Fewer workers per retiree, escalating fiscal pressure on healthcare systems
55M+ Americans 65+
Already over 55 million Americans aged 65 or older today. [3]
80M By 2040
Projected 65+ population will reach almost 80 million. [1]
20% of Population
1 in 5 Americans will be 65+ by 2030. [1]
5× Cost Multiplier
Per-person spending for 65+ is 5× higher than for children. [1]
Cost Reality
Structural, Compounding Medical Inflation
Without interventions that alter the trajectory of age-related disease, cost curves remain exponential
$172,500 Per Retiree
Average healthcare cost during retirement, more than doubled since 2002. [5]
7-8% Annual Increase
Expected healthcare cost growth for US employers in 2025. [6]
2.5× vs Working Age
Per-capita spending for 65+ compared to working-age adults. [1]
The Opportunity
Biotech Can Bend the Cost Curve
Solutions that extend healthspan, reduce costs, and improve lives
If 90% of spend is tied to chronic conditions linked to aging, even single-digit percentage reductions cascade into hundreds of billions in savings.
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
Aging Population: The Longevity Opportunity
Why Now
The Global Aging Wave
A demographic shift creating a multi-trillion dollar opportunity
2B
people over 60 by 2050
United Nations
Explore
Demographics
A Defining Global Trend
The UN describes global aging as "a defining trend of our time" and a "major success story"
2.1B People 60+ by 2050
The UN projects the global population aged 60+ will roughly double to 2.1 billion by 2050. [1]
1.6B People 65+ by 2050
Population aged 65+ expected to reach around 1.6 billion, nearly double today's 857 million. [2]
3x Growth in 80+ Population
The "oldest old" (80+) will more than triple from 127M in 2015 to 447M by 2050. [2]
1 in 4 Asians over 60 by 2050
In Asia, one in four people will be over 60, with some economies nearing 40% aged 65+. [3]
Breakthroughs
Science at an Inflection Point
Validated genomic tools, mechanism-based geroscience, and AI-native R&D have transformed longevity into an investable category
CRISPR & Genetic Interventions
Evolved from basic gene editing to base editing, prime editing, and epigenome editing—enabling precise interventions in age-related pathways.
Senolytics
Drugs that selectively clear senescent "zombie" cells, implicated in chronic inflammation and age-related diseases.
AI-Driven Drug Discovery
Applied to multi-omics datasets and biomarker streams to identify aging signatures and enable biological-age-driven interventions.
Opportunity
The Longevity Economy
A multi-trillion dollar market underpinned by demographic certainty
25% of Global Consumption
Seniors will account for one-quarter of global consumption by 2050, double their share in 1997. [4]
$7T+ Longevity Economy
Healthcare, financial products, housing, caregiving, and consumer markets serving older adults. [4]
77 years Life Expectancy by 2050
Global life expectancy projected to reach 77 years by 2050, up from 73 years in 2023. [4]
Join Us
Capture the $7T+ Longevity Economy
Demographic inevitability meets scientific readiness
Our Differentiation: Why Dark Matter
Why Dark Matter
Our Differentiation
Scientific depth, exclusive access, and tight focus on defensible longevity technologies
Explore
Competitive Advantages
Four Pillars of Differentiation
Deep Scientific Expertise
in longevity biology
- Decades of experience across biology, data science, and company-building
- Embedded in leading geroscience centers working to extend healthspan
- Distinguish true mechanism-based therapies from superficial wellness products
- Support portfolio companies with trial design, regulatory strategy, and biomarker selection [1] [2]
Proprietary Deal Flow
via Stanford & Cedars-Sinai partnerships
- Early visibility into spin-outs, pilot projects, and translational teams
- Access to key investigators and clinical trial infrastructure
- Co-design company formation around validated science and IP
- NIH-backed aging clinical trials and gerotherapeutics programs [3] [4]
Longevity Leader Network
Ben Greenfield, Bryan Johnson, Peter Attia
- Platforms reaching millions of longevity-focused consumers and clinicians
- Real-world testing grounds with highly engaged, data-rich users
- Credible distribution, education, and awareness channels
- Direct feedback from athletes, biohackers, and prevention-oriented patients
IP-Protected, Scalable Solutions
Focus on defensible platforms
- Novel therapeutics targeting fundamental aging pathways
- Diagnostic, digital, and AI-driven tools for personalized interventions
- Strong intellectual property moats and clear regulatory paths
- Measurable impact on healthspan—clinically meaningful outcomes [1] [2]
The Team
Team-Enabled Advantages
Our differentiation is not theoretical—it's embedded in who we are
Skinner Layne
Strategy & Capital Formation
Builds structures that bridge scientific discovery with institutional LP expectations.
Deep
Mark Moline
Investment Analysis
Translates scientific narratives into investment-grade theses.
Proprietary
Thomas Vu
Operations & Scale
Scaling products from early validation to mass adoption.
Longevity
Anthony Borquez
Commercialization
Driving user acquisition, partnerships, and go-to-market execution.
IP-Protected,
Partner With Us
A Team That Speaks Both Lab and Late-Stage Capital
Scientific depth meets investment discipline
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
Exit Potential: IPOs & M&A
Returns
Exit Potential
Two proven paths to liquidity for longevity investments
$2B+ Longevity IPOs in 2023
[1]
17.9% Anti-aging Market CAGR
[2]
$5B+ Startup Funding in 2023
[1]
Explore
Exit Paths
Two Proven Routes to Liquidity
IPOs in Public Markets
Biotech IPOs remain a core liquidity event, especially for companies with differentiated clinical data in age-related disease.
-
Quality Over Quantity
The post-2021 correction led to a disciplined IPO market focused on clinical-stage, de-risked assets. [3]
-
100% Clinical-Stage
By 2023, all US biotech IPOs had clinical-stage assets, with roughly one-third at Phase III. [3]
-
Mainstream Theme
Longevity-focused biotechs raised over $2 billion via IPOs in 2023 alone, signaling aging biology as investable. [1]
-
Data-Driven Stories
Investors reward platforms that pair bold aging biology with credible, near-term milestones. [4]
Acquisitions by Big Pharma
Large pharma companies facing patent cliffs are increasingly acquiring longevity-adjacent assets to sustain growth.
-
Massive Market Growth
Global anti-aging therapeutics projected to grow from $5.7B (2024) to $34.6B by 2035. [2]
-
M&A as Core Return Driver
Institutional investors expect continued M&A as pharma uses acquisitions to access innovative platforms. [3]
-
Strategic Fit
Longevity mechanisms intersect with existing pharma markets—cardiometabolic, oncology, ophthalmology. [5]
-
VC Capital Precursor
Longevity VC funds raised over $3B in 2023, seeding future acquisition targets. [1]
Market Opportunity
Anti-Aging Therapeutics Market
$5.7B 2024
17.9% CAGR
$34.6B 2035
Global anti-aging therapeutics market projection [2]
Deal Structure
Example Deal Structure
Pharma–Senolytics Acquisition Model
Strategic Rationale
- Large pharma seeking next-generation assets that modify fundamental aging biology
- Senolytics address shared mechanisms across multiple age-related diseases
- One asset with potential across several multi-billion-dollar indications
Based on recent longevity M&A activity [5]
Illustrative Terms
- Target
- Clinical-stage senolytics company
- Buyer
- Top-10 global pharma
- Upfront
- $500M–$1B cash
- Biobucks
- $2B–$4B milestones
The Opportunity
Exits Don't Require Full Lifespan Extension
Credible age-related disease indications are sufficient for pharma-scale exits
Fund Strategy: Portfolio Construction
Portfolio Construction
Fund Strategy
Portfolio construction designed for category-defining longevity outcomes
$100M Fund Size
10 Year Term
25 Target Investments
Explore
Economics
LP-GP Alignment
2% Management Fee
Annual on committed capital
20-25% Carried Interest
Performance fee, back-ended
Meaningful GP Commitment
Personal capital alongside LPs
Capital Deployment
Stage Allocation
50%
Seed
Lead or co-lead in technical and scientific founding teams
Core longevity biology, platform technologies, enabling tools
30%
Series A/B
Scale capital into companies showing human data and traction
Clinical validation, strategic partnerships, commercial progress
20%
Follow-ons
Systematic double-down into top decile outcomes
Concentrated capital behind proven winners
Geography
Geographic Focus
70/30 Split
U.S. / Europe 70%
Best-in-class research hubs with deep biotech talent and established exit markets
Rest of World 30%
Opportunistic positions in Israel, Asia, and emerging innovation clusters
Investment Approach
Check Sizes & Ownership
$2.75M–$3.0M Initial Check
Per company at entry
10–15%+ Target Ownership
At seed entry
$5M–$10M Winner Reserves
Per breakout company
Capital Concentration
Follow-On Strategy
Concentrate capital behind the most promising longevity platforms as evidence accumulates
Top 3-5 Companies
$5M–$10M+ Lead or participate meaningfully in multiple subsequent rounds
High-single to low-double digit ownership into late stages
Next 8-10 Companies
$3M–$5M Support through key de-risking milestones
First-in-human data, partnerships, reimbursement validation
Remaining Companies
Pro-rata only Capital not trapped in low-conviction situations
Preserve dry powder for true outliers
LP Value
How This Serves LPs
1
Balanced Diversification
~25 core positions across the longevity stack with meaningful concentration in winners
2
Stage Mix Advantage
Seed taps early entry pricing; A/B compounds into validated companies
3
Systematic Framework
Written reserve rules avoid emotional decisions, focusing on highest risk-adjusted MOIC
Institutional Grade
Venture Returns from the Longevity Ecosystem
Category-defining companies through critical inflection points